PPARs Mediate Lipid Signaling in Inflammation and Cancer
Open Access
- 21 December 2008
- journal article
- review article
- Published by Hindawi Limited in PPAR Research
- Vol. 2008, 1-15
- https://doi.org/10.1155/2008/134059
Abstract
Lipid mediators can trigger physiological responses by activating nuclear hormone receptors, such as the peroxisome proliferator-activated receptors (PPARs). PPARs, in turn, control the expression of networks of genes encoding proteins involved in all aspects of lipid metabolism. In addition, PPARs are tumor growth modifiers, via the regulation of cancer cell apoptosis, proliferation, and differentiation, and through their action on the tumor cell environment, namely, angiogenesis, inflammation, and immune cell functions. Epidemiological studies have established that tumor progression may be exacerbated by chronic inflammation. Here, we describe the production of the lipids that act as activators of PPARs, and we review the roles of these receptors in inflammation and cancer. Finally, we consider emerging strategies for therapeutic intervention.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
This publication has 146 references indexed in Scilit:
- Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatmentDrug Resistance Updates, 2008
- NF-κB and cancer—identifying targets and mechanismsCurrent Opinion in Genetics & Development, 2008
- Modulation of PPAR activity via phosphorylationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- PPARγ in human and mouse physiologyBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Unravelling the pathogenesis of inflammatory bowel diseaseNature, 2007
- Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studiesThe Lancet, 2007
- Opposing Effects of Retinoic Acid on Cell Growth Result from Alternate Activation of Two Different Nuclear ReceptorsCell, 2007
- The PPARγ Agonist Rosiglitazone Impairs Colonic Inflammation in Mice with Experimental ColitisJournal of Clinical Immunology, 2007
- PPARγ agonists prevent TGFβ1/Smad3-signaling in human hepatic stellate cellsBiochemical and Biophysical Research Communications, 2006
- NF-κB: linking inflammation and immunity to cancer development and progressionNature Reviews Immunology, 2005